Cell line · CVCL_2690
PEO4
Cancer cell line, Homo sapiens. BRCA2 syndrome. 39 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. PEO4. Cell lines, record CVCL_2690. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_2690
On this page
Cell line
As Cellosaurus gives it.
- Name
- PEO4
- Accession
- CVCL_2690
- RRID
- RRID:CVCL_2690
- Synonyms
- PE04, PEO-4
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- Age unspecified
- Category
- Cancer cell line
- Diseases
- BRCA2 syndrome (NCIt C36101); Ovarian cystadenocarcinoma (NCIt C5228); Hereditary breast and ovarian cancer syndrome (ORDO Orphanet_145)
- Derived from
- Ascites (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers39
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. | Br J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DHX9 Inhibition Enhances Paclitaxel Sensitivity by Inducing Mitotic Failure in Ovarian and Endometrial Cancers. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. | Adv Biol (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metabolic Dependency on De Novo Pyrimidine Synthesis Is a Targetable Vulnerability in Platinum-Resistant Ovarian Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage. | Nat Cell Biol | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 39
See all 39 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | PEO4-iPSC-OSKM-03 | CVCL_B7JI | Cell lines | |
| Derived from it | PEO4-iPSC-OSKM-05 | CVCL_B7JJ | Cell lines | |
| From the same person | PEO1 | CVCL_2686 | Cell lines | |
| From the same person | PEO6 | CVCL_2691 | Cell lines |
Cell banks3
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| CancerTools | 151673 | CancerTools | |
| ECACC | 10032309 | Discontinued | Cellosaurus |
| Ximbio | 151673 | Ximbio |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2690
GET https://conductscience.org/api/cell-lines/v1/CVCL_2690/papers?page=2